Global Antidiabetics Market Growth 2023-2029

Global Antidiabetics Market Growth 2023-2029

Type 1 Diabetes and Type 2 Diabetes are common types of diabetes. Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract.

LPI (LP Information)' newest research report, the “Antidiabetics Industry Forecast” looks at past sales and reviews total world Antidiabetics sales in 2022, providing a comprehensive analysis by region and market sector of projected Antidiabetics sales for 2023 through 2029. With Antidiabetics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antidiabetics industry.

This Insight Report provides a comprehensive analysis of the global Antidiabetics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antidiabetics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antidiabetics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antidiabetics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antidiabetics.

The global Antidiabetics market size is projected to grow from US$ 56910 million in 2022 to US$ 84910 million in 2029; it is expected to grow at a CAGR of 84910 from 2023 to 2029.

The North American antidiabetics market held the largest market revenue share in 2013. High market penetration of modern insulin products such as long-acting, rapid acting insulin analogs and DPP-4 drugs such as Januvia, Onglyza and Nesina and the presence of high healthcare expenditures, patient awareness levels, sophisticated healthcare infrastructure and reimbursement framework are the major factors contributing to its large share.

Asia Pacific on account of the rapidly improving healthcare expenditure levels, growing prevalence of type I and type II diabetes and increasing patient disposable incomes is expected to grow at the fastest rate during the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Antidiabetics market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Type 1 Diabetes
Type 2 Diabetes
Other

Segmentation by application
Hospital Use
Clinic Use
Household
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi-Aventis
Takeda Pharmaceuticals
Eli Lilly
Oramed Pharmaceuticals
Boehringer Ingelheim
Merck & Co. Inc.
Novo Nordisk
Bristol-Myers Squibb
Halozyme Therapeutics
Pfizer

Key Questions Addressed in this Report

What is the 10-year outlook for the global Antidiabetics market?

What factors are driving Antidiabetics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Antidiabetics market opportunities vary by end market size?

How does Antidiabetics break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.